Description：Immunoassay for quantitative estimation of Enfuvirtide in human serum, plasma and tissue extracts.
Enfuvirtide （INN） is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection.
Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
About the kit：
- Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
- Recovery rates are between 85 - 115％
- Ready to use with a standard protocol with break-apart pre-coated wells
- Validated as per US FDA guidelines for Bioassays
- Optimized for matrix effects to ensure higher sensitivity.
- Shelf life： 1 year
The Enfuvirtide ELISA is a sandwich immunoassay for the determination of Enfuvirtide.
The antibodies coated on a 96-well plate capture the standard or sample.Enfuvirtide antiserum is subsequently bound to this complex.
Biotin is then added followed by SA-HRP （streptavidin-conjugated horseradish peroxidase）, which produces a soluble colored product after a substrate is added.
The enzyme reaction is stopped by dispensing an acidic solution （H2SO4） into the wells after 10 min at room temperature turning the solution from blue to yellow.
The optical density （OD） of the solution at 450 nm is directly proportional to the amount of specific Enfuvirtide bound.
